Could a smaller dose of monkeypox vaccine work just as well?
NCT ID NCT05512949
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether giving a smaller dose of the MVA-BN (JYNNEOS) monkeypox vaccine under the skin works as well as the standard full dose given into the muscle. About 229 healthy adults aged 18 to 50 received either one-fifth or one-tenth of the standard dose under the skin, or the full dose into the muscle. Researchers measured immune responses to see if the lower doses were non-inferior to the standard regimen.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MVA-BN vaccine (JYNNEOS)
What this could lead to
If successful, this could show that smaller doses of the monkeypox vaccine given under the skin are just as effective, allowing more people to be vaccinated with the same supply.
What could go wrong
This is a Phase 2 trial with only 229 healthy adults, so results may not apply to everyone. Lower doses might not provide the same level of protection as the standard dose.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MONKEYPOX are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baylor College of Medicine
Houston, Texas, 77030-3411, United States
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115-6110, United States
-
George Washington University Medical Faculty Associates
Washington D.C., District of Columbia, 20037, United States
-
NIH Clinical Research Center, Investigational Drug Management and Research Section
Bethesda, Maryland, 20892-1504, United States
-
Saint Louis University Center for Vaccine Development
St Louis, Missouri, 63104-1015, United States
-
The Hope Clinic of Emory University
Decatur, Georgia, 30030, United States
-
University of California, San Diego (UCSD) - Antiviral Research Center (AVRC)
San Diego, California, 92103-8208, United States
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37212, United States